Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
Lancet. 2020.
PMID: 32416780
Clinical Trial.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators.
Fizazi K, et al.
N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16.
N Engl J Med. 2023.
PMID: 36795891
Free PMC article.
Clinical Trial.
Item in Clipboard
[Treatment of the patient with castration-resistant biochemical progression of prostate cancer].
Arija JA, Beca RG, López CL, Domínguez PS, Lovelle AS, Gilarranz YJ.
Arija JA, et al.
Arch Esp Urol. 2012 Jan-Feb;65(1):185-92.
Arch Esp Urol. 2012.
PMID: 22318189
Review.
Spanish.
Item in Clipboard
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ, González-Del-Alba A, López-Campos F, López López C, Requejo OH, de Castro Carpeño J, Chicas-Sett R, de Paz Arias L, Montero-Luis Á, Pérez AR, Font EF, Arija JÁA.
Conde-Moreno AJ, et al. Among authors: arija jaa.
Clin Transl Oncol. 2023 Apr;25(4):897-911. doi: 10.1007/s12094-022-03019-y. Epub 2022 Dec 16.
Clin Transl Oncol. 2023.
PMID: 36525230
Item in Clipboard
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.
Vergote I, et al.
Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.
Lancet Oncol. 2019.
PMID: 31076365
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite